Last Week in GER Research: Meituan, IPO Trading Strategy, Shandong Gold, Maoyan and Viomi
Below is a recap of the key IPO research produced by the Global Equity Research team. This week we highlight that Meituan is closer to fair value...
336 Views
Last Week in GER Research: Meituan, Nio, Haidilao, Shandong Gold, China Renais., X Financial and PDD
Below is a recap of the key IPO research produced by the Global Equity Research team. This week we dig into the economics of Mobike as it relates...
372 Views
Last Week in GER Research: Meituan, China Tower, Haidilao, Qutoutiao, Hua Med., Chunlai, and Cootek
Below is a recap of the key IPO research produced by the Global Equity Research team. This week we assess Meituan's latest results ahead of its...
328 Views
Last Week in GER Research: Meituan-Dianping, Nio, Gangfeng Lithium, Pinduoduo and 111 Inc
Below is a recap of the key IPO and fundamental research produced by the Global Equity Research team. This week we highlight a more palatable...
337 Views
Hua Medicine IPO Preview: Suffering from the Ascletis Over-Valuation Syndrome
Hua Medicine Ltd (2552 HK) which specialises in developing drugs to treat Type 2 diabetes, is the third pre-profit biotech firm to IPO in Hong Kong...
792 Views